Oxford BioMedica is a biopharmaceutical company that develops novel gene based therapeutics with a focus on neurotherapy and oncology. The company has an extensive preclinical and research portfolio of products in various phases, including neurotherapy products in preclinical development and two anticancer products in clinical trials. Oxford BioMedica’ products and technology include TroVax®, MetXia®, ProSavin®, RetinoStat®, MoNuDin® etc. The company had an annual turnover of US$0.74 M in 2003.